ESTABLISHED
JUNE 1978
HEAD QUARTER
SEOUL, KOREA
EMPLOYEES
ABOUT 650
| CEO & President | Wonbum Lee |
|---|---|
| Sales Revenue(2024) | 257,969 Million KRW |
| Stock Exchange Index | KOSPI |
| Head Office | Seoul, Korea |
| KGMP Plant | Anseong, Korea / Hyangnam, Korea |
| R&D center | Yongin, Korea / Seoul, Korea |
| Main Therapeutic Areas | Central Nervous System (80%) Cardiovascular (5%) Gastrointestinal (2%) |
| Main Products | Quetiapine/Agomelatine/Escitalopram/Donepezil |
